TSH-suppressive therapy

PreclinicalSmall molecule

TThe Affiliated Hospital of Inner Mongolia Medical University

TSH-suppressive therapy is one of 12 small molecule programs targeting Differentiated Thyroid Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Differentiated Thyroid CarcinomaActive, not recruiting

Differentiated Thyroid CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Differentiated Thyroid Carcinoma

#DrugCompanyPhaseTrials

Tafinlar

Novartis

Phase 3

1 2

Mekinist

Novartis

Phase 3

1 3

Cotellic

Roche

Phase 2

1 4

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

2 5

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

1 6

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 2

1 7

AL2846

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 8

Nexavar

Bayer

Preclinical

—9

Radioactive Iodine Therapy

AstraZeneca

Phase 2

—10

Tirosint

IInstitut Jerome Lejeune

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Differentiated Thyroid Carcinoma1 trial

Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma

Unknown status·TThe Affiliated Hospital of Inner Mongolia Medical University··NCT02665325·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TSH-suppressive therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TSH-suppressive therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TSH-suppressive therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Inner Mongolia Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Affiliated Hospital of Inner Mongolia Medical University

TSH-suppressive therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Differentiated Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News